342 Index Name Paper ref. Name Paper ref. Kemény, A W19.3 Kemme, M Thu 215 Kemter, K Thu 014 Kendall, DA Mon 282 Kennedy, P Wed 076 Keown, O Mon 211 Keres Kos, M FC07.3.5 Kereskai, L Mon 283, W19.3 Keri, G Tue 250 Kerr, R Wed 316 Kersten, S Thu 438, FC18.2.5 Keshavarz, M Tue 058 Ketelslegers, J Tue 182 Ketola, K Mon 410, Tue 436 Keum, S-K Mon 069, Tue 331, Tue 332, Tue 333 Kezeli, T Wed 272 Khadke, VV Wed 381 Khairatkar Joshi, N W03.2 Khakpour, SH FC17.2.6 Khalaf, M Thu 247 Khalifa, HM Mon 364 Khalili-Mahani, N Mon 400 Khalkhali, H Thu 391 Khan, A Tue 119, Wed 356 Khan, GM Tue 023 Khan, MAH FC05.1.5 Khan, S Wed 355 Khan, UA Tue 319 Khanam, R Wed 419 Kharazmi, F Tue 058 Khare, Ah Wed 381 Kharel, Y Tue 410 Khaylov, N Wed 248 Khayyal, M T Wed 382 Khazaee, P Tue 231, Khazali, S Mon 002 Kheifets, IA Thu 015 Khemawoot, P Tue 090 Kheyfets, IA Mon 198 Khodadadi, A Tue 251 Khoddami, M Tue 052 Kholova, D Tue 056, Tue 342 Khorami, H Thu 004 Khori, V Mon 196 Khotimchenko, M Mon 426 Khotimchenko, Y Mon 426 Khoza, S Tue 004 Kido, M Wed 141 Kieffer, B L FC11.4.4 Kihira, Y Mon 180 Kilibarda, V Tue 321 Kilic, FS Wed 420, Mon 103, Wed 421 Kilinc, E Mon 043 Kilpinen, S Tue 436 Kilty, I Tue 269 Kim, CM Tue 334 Kim, E-J Wed 383 Kim, H-G Tue 335 Kim, H-S Tue 351 Kim, IK Wed 274, Wed 384, Wed 275 Kim, J-H Wed 306, Wed 385 Thu 385 Kim, JY Wed 276 Kim, J-W Tue 335 Kim, JY Mon 062 Kim, K-S Tue 334, Wed 383 Kim, M-J Mon 049, Mon 065, Mon 066, Mon 069, Mon 358, Mon 359, Tue 043, Tue 044, Tue 073, Tue 162, Tue 323, Tue 324, Tue 333, Tue 350, Wed 142, Wed 143 Kim, R FC02.1.6, 072, Tue 054, Tue 064, Mon Tue 301 Kim, RB FC02.3.1 Kim, SA Mon 428, Mon 427, Wed 277 Kim, S-R Tue 335 Kim, W-Y Tue 352 Kimbacher, S Mon 218 Kimland, E Wed 008 Kimoto, Y Thu 320 Kimura, J Tue 071 Kimura, M Tue 390 Kinjo, T Wed 075 Kinoshita, Y Wed 117, Tue 273, Tue 336, Tue 337, Tue 483 Kinscherf, R Mon 317, Tue 462 Kinsey, S Tue 353 Kinyua, CG Wed 298 Kiraly, I Wed 284 Kirchheiner, J Mon 384, Mon 315, Wed 148, Thu 112 Kirchmayer, J Thu 014 Kirkeby, B Wed 161 Kirkpatrick, C Wed 125, Wed 126 Kis, O Mon 070 Kishida, I Wed 422 Kishuku, M Wed 278 Kisida, I Wed 415 Kiss, B Wed 423 Kis-Varga, Á Tue 078 Kita, S Thu 286 Kitagawa, T Wed 247 Kitaichi, K Thu 406 Kitamoto, T Mon 435 Kitamura, T FC13.2.5, Tue 126 Kitamura, Y Wed 413, Wed 424, Thu 261, Tue 415 Kitano, H FC07.1.2 Kitao, T Tue 060 Kitazawa, T Tue 468 Klaassen, T Mon 384, Mon 315 Klaerke, D Thu 106 Klapkova, E Tue 445 Klayoncu, NI Tue 027 Kleberg, K FC02.2.5, Mon 071 Klein, AB FC11.2.6 Klein, U Thu 069 Kleinau, G Thu 087 Kleinloog, HD FC17.3.5 Kleinschnitz, C FC15.4.4 Klemp, M Tue 143 Kliewer, SA FC18.1.3 Klimas, J FC05.4.5, Mon 219, Mon 221 Klimas, Jan Thu 097 Klindt Poulsen, B Thu 413 Klitgaard, T Mon 227 Kloppenburg, A Thu 101
Name Paper ref. Name Paper ref. Klouz, A W27.1, FC07.3.6, Mon 004, Mon 020, Mon 021, Mon 338, Wed 348, Thu 346 Kluft, C Mon 316 Klukovits, A Wed 050 Klumpers, LE Mon 400 Klungel, OH FC04.1.2 Klusa, V Mon 429, Tue 253, Wed 045 Kmecova, J Thu 097 Kmonícková, E Tue 300, Wed 386 Knani, J Mon 006 Knapp, A Mon 229 Knauer, M Mon 072 Kneepkens, K Wed 001 Kniazeff, J FC11.2.1, FC11.3.5, Mon 058, Mon 073, Wed 077 Knight, S Wed 425, Mon 430 Knowles, RG FC09.3.4 Knudsen, GM FC11.5.6, FC11.2.6 Knudsen, LB FC05.3.4 Knuhtsen, S Mon 071 Knuistingh-Neven, A Tue 096 Ko, J-W Tue 335 Ko, SSW Tue 140 Ko, YK Mon 104 Kobayashi, D Wed 078 Kobayashi, N Mon 307 Kobayashi, S Tue 273, Tue 336, Tue 380, Tue 483, Tue 492 Kobayashi, T Tue 315 Kobayashi, Y Tue 177, Mon 178 Kobayasi, S Tue 337 Køber, L FC13.3.6, FC04.2.4 Kobilka, B Wed 028 Kobilka, BK PL10, W01.1.2 Kobuchi, S Wed 200 Kocan, M W14.2, Wed 079, Wed 080 Kochar, S Tue 453 Kocic, I Wed 279, Mon 181 Koda, Ken Tue 360 Kodaira, C W23.4, Tue 473 Kodetova, D Tue 445 Koenig, J FC02.2.6 Koenig, S Tue 115 Koenig, X Mon 217, Mon 218 Koh, H-J FC05.2.6 Kohda, K Thu 402 Kohda, Y Tue 315 Kohjitani, A Mon 303 Kohler, R Thu 273 Kohonen, P Mon 410, Tue 436 Koike, Y Tue 084, Tue 338, Thu 285 Koistinaho, J W21.3 Koivula, K Wed 081 Koiwa, G Tue 122 Koizumi, N Tue 154 Kojima, J Wed 263 Kojima, S Tue 274 Kojo, A Mon 255, Mon 405 Kokkas, B Mon 300, Mon 297 Kokki, H Tue 339 Kokki, M Tue 339 Kolb, C Wed 417 Koley, M Mon 217 Kolik, L Wed 188 Kolkhof, P Thu 091 Kollia, G Tue 495 Kolliali, M Tue 102 Kolyvanov, G Tue 150 Komatsu, Y Tue 274 Komazaki, H Wed 061 Kombian, S Tue 340 Komsuoglu Celikyurt, I Thu 401, Wed 351 Komuro, I Thu 286 Koncz, I Mon 100 Kondo, Y Wed 186, Wed 263 Kondo, Yukiko Tue 477 Kondratenko, S Thu 114 Kong, SK Thu 381 Kong, S-S Tue 187, Tue 186 Kong, WCB FC15.2.6 Kongpatanakul, S Mon 334, Mon 355, Mon 357, Tue 007, Tue 341 Kongsiang, A Tue 007 Konhan, K Mon 357 König, F FC07.4.2 Konsman, J-P W11.1 Konturek, PC Tue 463 Konturek, SJ Tue 463 Konwar, R Wed 294 Koob, GF FC14.4.1 Koole, C Wed 082 Koolwijk, P Thu 216 Koon, CM Thu 297 Koon, JCM Wed 345 Kopanchuk, S Tue 192 Kopecky, J Tue 342, Thu 168 Koponen, J W21.3 Koren, G Wed 003, Wed 099, Wed 013 Korhonen, R W21.5, Tue 278, FC09.5.4, FC09.1.5, Tue 239 Koriyama, Y Tue 413 Korjamo, T Mon 060 Kormányos, Z Mon 208 Kormos, V Mon 110, Mon 106 Korpela, M FC09.2.5 Korpela, R Wed 361 Korpi, ER Wed 393, Thu 194, Thu 409 Korstanje, C W01.3.2 Korth-Bradley, J Tue 012 Koshelev, V Wed 283 Koshimizu, T Wed 189 Koskimies, P Wed 446 Koskinen, A Tue 283 Koskinen, P Tue 429 Kostantinidis, G FC10.2.6 Kostenis, E FC11.1.6 Kostkova, L Tue 113 Kostowski, W Thu 174 Kostrzewa, A Tue 092 Kotani, T Tue 274 Kotoula, M Tue 246 Kotsar, A Thu 223 Kotyzová, D Mon 409 Kou, Y Mon 078 Kouchi, K FC03.4.5 Koutani, A Wed 083 Koutsioumpa, M Thu 232 Index 343
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295: W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 346 and 347: 344 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor